DSGN earnings analysis
What we found in DSGN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Design Therapeutics remains a pre-revenue clinical-stage company, reporting a Q2 2026 EPS loss of $0.32, modestly better than the $0.34 loss a year ago but worse than the $0.29 loss in Q1. Liquidity of $207.4 million and an additional $19.9 million raised through the ATM provide more than 12 months of planned funding, but six-month operating cash burn was $32.0 million and further capital will be needed before regulatory approval. The central catalyst is 12-week DT-216P2 RESTORE-FA data expected in Q1 2027; DT-168 data were delayed to 2027 due to packaging supply constraints.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- EPS improved year over year, worsened sequentially
- The Q2 diluted EPS loss was $0.32, improving by $0.02 from a $0.34 loss in Q2 2025, though worsening by $0.03 from a $0.29 loss in Q1 2026. The company has no approved products and reported no product-sale revenue.
- Cash supports more than 12 months of operations
- Cash, cash equivalents and investment securities were $207.4 million at June 30, 2026, down $12.4 million from $219.8 million at December 31, 2025. Management believes this balance funds planned operating expenses and capex for more than 12 months.
- ATM bolstered liquidity amid operating cash burn
- Six-month operating cash use was $32.0 million, versus $31.2 million a year earlier. The company raised approximately $19.9 million through the sale of 2,006,550 shares under its ATM program, leaving $53.9 million available under that facility.
- R&D investment rose modestly for FA development
- Q2 R&D expense increased 4% to $16.4 million from $15.7 million, driven by FA clinical activity and indirect costs, while G&A declined $0.04 million to $5.8 million. Total operating expense rose $0.6 million to $22.2 million.
- Early DT-216P2 biomarker and clinical activity
- In RESTORE-FA's 1 mpk cohort of 4 patients, four-week treatment produced mean improvements of 6.4 points in mFARS and 2.7 points in upright stability; whole-blood FXN mRNA increased 65%. No serious adverse events or discontinuations were reported.
- Portfolio development advanced across FECD and DM1
- The FECD observational study completed baseline assessments for approximately 250 patients and selected approximately 100 for follow-up. DM1 patient dosing began in the first half of 2026, expanding the clinical pipeline beyond FA.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Ongoing losses require future capital
- The company recorded a $37.8 million net loss and used $32.0 million in operating cash during the first six months of 2026. While it has $207.4 million of cash and securities, management states that current resources will not fund any product candidate through regulatory approval.
- Supply constraints delayed DT-168 data
- DT-168 Phase 2 biomarker-trial data are now expected in 2027 because of delayed supply of blow-fill-seal eye droppers. The company also reports only one supplier for an excipient component of DT-216P2, creating supply concentration risk.
- Early clinical dataset and safety monitoring risk
- RESTORE-FA's reported 1 mpk clinical results are based on only 4 patients and four weeks of treatment. Three patients had mild-to-moderate transient ALT elevations considered possibly or probably treatment-related, while 12-week data are not expected until Q1 2027.
- Future financing may dilute shareholders
- The company sold 2,006,550 shares for approximately $19.9 million through its ATM in the first half and retained $53.9 million of remaining ATM capacity. Further equity financing could dilute current holders as development spending grows.
- Clinical expansion raises future spending risk
- R&D expense is expected to increase as FA, FECD, DM1 and HD programs advance; Q2 R&D was already $16.4 million. The company had an accumulated deficit of $334.8 million as of June 30, 2026.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.32
What they said about what is next.
No financial revenue or EPS guidance was provided. Management expects a DT-216P2 registrational-plan update in Q4 2026, 12-week RESTORE-FA data in Q1 2027, and DT-168 and DT-818 data in 2027.
The filing reads about the same as the one before it.
What came before.
- 10-Q · April 28, 2026
- Design Therapeutics reported lower operating expenses in Q1 2026 with total operating expenses of $19.706 million, driven by a $998 thousand decline in R&D spend to $14.379 million and modestly higher G&A of $5.327…
- 10-K · March 19, 2024
- Design Therapeutics is an early-stage biopharma developing GeneTAC small molecules to address nucleotide repeat expansion diseases. The 10-K highlights program progress — IND clearance for DT-168 (FECD) in late 2023,…
- 10-Q · November 13, 2023
- Design Therapeutics remains a pre-revenue biotech with a Q3 net loss per share of $0.28, a sequential and year-over-year improvement versus $0.32 in Q3 2022 and a beat to consensus (estimate -$0.41). The company has…
- 10-Q · May 9, 2023
- Design Therapeutics reported a larger quarterly loss: net loss of $19,294 (‑$0.35 per share) in Q1 2023 versus $13,265 (‑$0.24) in Q1 2022, driven by higher operating expenses (total operating expenses $21,651 in Q1…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing DSGN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever